LakeShore Biopharma Gets Proposal from Oceanpine Capital
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 18 2025
0mins
Source: NASDAQ.COM
Acquisition Proposal: LakeShore Biopharma has received a preliminary non-binding proposal from Oceanpine Investment Fund II LP and Oceanpine Capital Inc. to acquire all outstanding shares not owned by Oceanpine for $0.86 per share in cash.
Board Review: The Board of LakeShore Biopharma will carefully evaluate the acquisition proposal to determine the best course of action for the company and its shareholders.
Shareholder Interests: The evaluation process aims to ensure that the decisions made align with the interests of both the company and its shareholders.
Disclaimer: The views expressed in the announcement are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
